Michelle Werner

Michelle Werner, CEO of Alltrna and advocate for rare disease treatments, shares her journey from big pharma to biotech, fueled by her child's diagnosis. She explains the revolutionary potential of engineered tRNA therapy, emphasizing its ability to address countless rare genetic diseases. The conversation dives into the innovative use of AI for drug optimization and the challenges of using lipid nanoparticles for effective tRNA delivery. Michelle also highlights the importance of support networks for women leaders in biotech and the significance of storytelling in patient advocacy.

Michelle Werner, CEO of Alltrna and longtime pharma leader, discusses engineered tRNA therapeutics inspired by her child's rare-disease diagnosis. She explains how tRNAs can read through premature stop codons, reframes nonsense mutations as a shared disease class, and covers delivery strategies, basket-trial approaches, CNS and muscle ambitions, and AI-driven design for a platform aiming to treat many genetic disorders.

Join Michelle Werner, CEO of Alltrna, who focuses on engineered tRNA therapeutics for rare genetic diseases, and Mike Severino, CEO of Tessera Therapeutics, specializing in RNA-based gene-writing platforms. They discuss how 2026 is a pivotal year for clinical trials, share groundbreaking preclinical results, and explore innovative strategies for addressing genetic mutations. The duo also highlights the importance of patient advocacy and the adaptability of their platforms to tackle various genetic disorders, marking a promising future in genetic medicine.